Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04853251 · ClinicalTrials.gov registry record · Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

A Phase 4 study of Neovascular Age-related Macular Degeneration, sponsored by Genentech.

Recruiting
Registry status
Phase 4
Development phase
188
Enrollment target
20
Study locations

NCT04853251 is a Phase 4 study of Neovascular Age-related Macular Degeneration that is actively recruiting participants, run by Genentech. The registered enrollment target is 188 participants, below the 403-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04853251, a Phase 4 study of Neovascular Age-related Macular Degeneration, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 4
Development phase
188 participants
Enrollment target
20
Study locations

Study Summary

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Conditions Studied

Neovascular Age-related Macular Degeneration

Interventions

  • DEVICE PDS Implant With Ranibizumab 100 mg/ml
  • DRUG LUCENTIS (Ranibizumab Injection)

Study Locations (20)

California

  • California Retina Consultants - Bakersfield
  • Retina Associates of Southern California - Huntington Beach
  • California Eye Specialists Medical group Inc. - Pasadena
  • Retinal Consultants Med Group - Sacramento
  • University of California San Francisco - San Francisco
  • Orange County Retina Med Group - Santa Ana
  • Macula Retina Vitreous Research Institute - Torrance

Florida

  • Retina Specialty Institute - Pensacola
  • Ft Lauderdale Eye Institute - Plantation
  • Retina Vitreous Associates of Florida - St. Petersburg

Colorado

  • Southwest Retina Consultants - Durango
  • Advanced Vision Research Institute - Longmont

Arizona

  • Barnet Dulaney Perkins Eye Center - Mesa

Connecticut

  • Retina Group of New England - Waterford

Georgia

  • Southeast Retina Center - Augusta

Illinois

  • University Retina and Macula Associates, PC - Lemont

Iowa

  • Wolfe Eye Clinic - West Des Moines

Trial Details

FieldValue
Enrollment Target 188 participants
Start Date 2021-12-14
Est. Completion 2028-04-30
Phase Phase 4

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04853251

The ClinicalTrials.gov registry entry for NCT04853251 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 403-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (53% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which PDS Implant With Ranibizumab 100 mg/ml is the first listed.

NCT04853251 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT04853251 about?

NCT04853251 is a clinical study titled "A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)". This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

What is the current status of trial NCT04853251?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 188 participants. The study started on 2021-12-14. Estimated completion is 2028-04-30.

What conditions does trial NCT04853251 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT04853251?

The interventions under investigation include: PDS Implant With Ranibizumab 100 mg/ml (DEVICE), LUCENTIS (Ranibizumab Injection) (DRUG).

Who is sponsoring clinical trial NCT04853251?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04853251 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neovascular Age-related Macular Degeneration

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.